BOSTON, MASSACHUSETTS — March 6, 2024 (GLOBE NEWSWIRE) — Bioxytran, Inc. (OTCQB: BIXT), a clinical-stage biotechnology company developing oral and intravenous therapeutics for viral diseases, today announced the publication of a preprint case study examining the use of a topical Galectin-3 antagonist in a patient with shingles.
The preprint, titled “Association of Rapid Shingles Lesion Clearance and Regression of Herpes Zoster Neuralgia in Case Study Using Topical Galectin-3 Antagonism,” was published on ResearchGate. The case study reported approximately 50% lesion clearance and regression of Herpes Zoster Neuralgia within 48–72 hours following treatment with a topical Galectin-3 antagonist.
Shingles, also known as herpes zoster, is caused by reactivation of the varicella-zoster virus. While vaccines are available to help prevent shingles, effective therapeutic approaches for treating active outbreaks while also addressing the associated pain remain an area of medical need.
The case study observed a rapid reduction in pain and lesion size following topical treatment with a Galectin-3 antagonist, providing preliminary human evidence supporting further investigation of galectin antagonism as a potential therapeutic approach for shingles and associated neuralgia.
The full pre-publication case study is available on ResearchGate:
Read the shingles case study on ResearchGate
“There are preventive vaccines for shingles of variable efficacy, but the search for an efficacious therapeutic intervention that terminates clinical progression of shingles has so far proven elusive,” said Dr. Leslie Ajayi, Chief Medical Officer of Bioxytran.
“This case study constitutes a proof of concept of the benefit of using a galectin antagonist in human shingles infection. If research dollars are available, we would like to conduct an expanded clinical series with a topical formulation of our Galectin-3 antagonists in a more varied patient pool consisting of 20 to 30 men and women.
“In parallel, we would like to examine the efficacy of an orally active Galectin-3 antagonist compared to the topical preparation, with the ultimate goal of conducting a randomized controlled trial against the standard of care (SOC).
“If our hypothesis is supported by clinical evidence, it may cause a paradigm shift and benefit the management of shingles and herpetic neuralgia. The subsequent possibilities are enormous and could have an impact in the fields of virology, dermatology, and neuroscience.”
Bioxytran, Inc. is a clinical-stage biotechnology company developing a library of novel carbohydrate structures using artificial intelligence-enabled drug design. The Company's platform uses Nuclear Magnetic Resonance (NMR) imaging of druggable targets, including the galectin fold, to support rational drug design.
Bioxytran's leading drug candidates have been evaluated through in vitro testing for antiviral activity. Research into the galectin fold found on the spike proteins of viruses such as COVID-19, RSV, and H1N1 has identified a conserved region of the viral spike that Bioxytran's molecules are designed to target for virus neutralization.
The Company's platform technology is being explored for applications addressing significant unmet medical needs across virology, degenerative diseases, and hypoxia.
Bioxytran's leading drug candidate, ProLectin-M, is a novel antiviral drug candidate designed to antagonize galectins implicated in inflammatory, fibrotic, and malignant diseases. The Company's other development programs include therapeutic approaches for pulmonary fibrosis and stroke.
This press release contains forward-looking statements as defined under federal law, including statements concerning the potential performance and applications of the technology described in this press release. These forward-looking statements are generally identified by words such as “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” and similar expressions, although not all forward-looking statements contain these identifying words.
Such statements are subject to significant risks, assumptions, and uncertainties. Known material factors that could cause Bioxytran's actual results to differ materially from those contemplated by these statements are described in the forward-looking statements and risk factors included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as well as in other filings made by the Company with the Securities and Exchange Commission from time to time.
Bioxytran undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events, or otherwise, except to the extent required under federal securities laws.
Bioxytran, Inc.
Website: www.bioxytraninc.com
Investor Contact:
Michael Sheikh
509-991-0245
mike.sheikh@bioxytraninc.com
